{{Infobox company
| company_name  =  Hologic
| company_logo  = [[File:Hologiclogo.jpg|250px]]
| company_type  =  [[Public company|Public]]
| traded_as  = {{NASDAQ|HOLX}}
| foundation  =  1985
| location  =  [[Bedford, Massachusetts]], [[United States|U.S.]]
| key_people  =  S. David Ellenbogen<br />Founder & former CEO/Chairman<br />Jay A. Stein<br />Chief Technical Officer<br />Robert Cascella<br /> current CEO
| industry  =  [[Medical devices|Medical products]]
| products  =
| revenue  =
| operating_income  =
| net_income  =
| num_employees  =  3000
| parent  =
| subsid  =
| homepage  =  [http://www.hologic.com/index.html www.hologic.com]
| footnotes  =
}}

'''Hologic''' corporation is a developer, manufacturer and supplier of diagnostic and medical imaging systems related to women's health.  It develops digital imaging technology for general radiography and mammography applications. Its core business units are focused on [[osteoporosis]] assessment, [[mammography]] and breast [[biopsy]], direct-to-digital x-ray for general radiography applications and mini C-arm imaging for orthopedic applications. Its major brands include Lorad, Fluoroscan, Selenia, Securview, Discovery, Multicare and Directray.

Hologic is a leader in women's healthcare, particularly [[breast cancer]] diagnosis.<ref>[http://www.forbes.com/markets/2007/05/21/hologic-cytyc-cancer-markets-equity-cx_er_0521markets03.html Hologic's Expensive Match-Up - Forbes.com]</ref>

Hologic is currently developing [[tomosynthesis]] technology for breast cancer diagnosis. Hologic first demonstrated the technology at the Radiological Society of North America in November 2003. It provided patient images and a prototype add-on to its Selenia [[digital mammography]] system. Clinical trials for Hologic's tomosynthesis technology began in the summer of 2004.<ref name=autogenerated1>[http://www.hoise.com/vmw/04/articles/vmw/LV-VM-12-04-37.html Hologic receives Frost & Sullivan's 2004 Technology Leadership of the Year Award in women's health diagnostics for breast cancer]</ref>

Hologic was the recipient of Frost and Sullivan's 2004 Technology Leadership of the Year Award in women's healthcare.<ref name=autogenerated1 />

==Hologic/Cytyc Merger==

On May 20, 2007, Hologic announced a merger (via a cash and stock transaction) with the [[Cytyc|Cytyc Corporation]] to create a $10 billion women's healthcare company with over $1 billion in projected annual sales.<ref>http://www.forbes.com/feeds/ap/2007/05/21/ap3740939.html</ref> The new company name will be "Hologic" and Cytyc will be a wholly owned subsidiary. The combined corporation will deal in products for screening, diagnostics and therapy for breast and [[cervical cancer]], [[menorrhagia]], prenatal health, osteoporosis, [[endometriosis]] and permanent [[contraception]].<ref>[http://www.clpmag.com/clprime/2007-05-30_01.asp Hologic, Cytyc Merge | May 30, 2007 | CLPrime | Clinical Lab Products<!-- Bot generated title -->]</ref> The brands under the combined company include, ThinPrep, Lorad, NovaSure, Suros ATEC, Discovery, Rapid fFN, R2 and MammoSite, and it will have operations in over twenty countries.<ref name=autogenerated2>http://news.corporate.findlaw.com/prnewswire/20070520/20may20071503.html</ref> Patrick Sullivan, of Cytyc will be chairman of the new company, and Jack Cumming, of Hologic, will be Chief Executive Officer.<ref name=autogenerated2 /> Cytyc shareholders will hold 55% of the firm, and Hologic will own 45%.

==Hologic/Gen-Probe Merger==

On April 30, 2012, Hologic announced a merger with Gen-Probe for about $3.72 billion by cash.

==References==
{{Reflist}}

==External links==
*[http://www.hologic.com Hologic]

{{Portal|Companies}}

[[Category:Companies based in Massachusetts]]
[[Category:Companies established in 1985]]
[[Category:Health care companies of the United States]]
[[Category:Companies listed on NASDAQ]]